A TRP that makes our cells feel hyper

A large change in the volume of a cell, from its basal level, is detrimental to its health. Therefore, our cells are equipped with mechanisms to maintain their constant volume. When a cell detects an environmental change that will alter its volume, due to changes in the osmotic pressure, it will adjust its internal water content to counter these influences. This is done through the movement of ions into, and out of, the cell through specialised ion channels. However, the identity of the molecules responsible for this phenomenon remain largely unknown. Professor Yasunobu OKADA, the Director-General of The National Institute for Physiological Sciences and the Vice-President of the National Institutes of Natural Sciences, and his research team, have identified the key molecule preventing the shrinking and eventual death (apoptosis) of cells when they are subjected to a condition of hyperosmolarity.

This is where there is an abnormal increase in the osmolarity of a solution, and can occur due to processes such as dehydration from or superfluous salt. The molecule they describe is a variant of TRPM2, containing a truncated C terminus. TRPM2 is member of the TRP family, a group of known to be involved in altering sensations including pain, temperature, pressure, taste and vision. It was further revealed that the TRPM2∆C molecule was activated through its binding to CD38 (cyclic ADP-ribose hydrolase), a glycoprotein associated with HIV infection, cancer, type II diabetes mellitus, and oxytocin secretion, among other things.

Professor Yasunobu OKADA expects that the newly identified molecule research should open doors into new avenues of research into these diseases, and aid in, not only, the elucidation of their pathological characteristics, but also their potential treatments in the future.

This research result has been published in the February issue of the Journal of Physiology (London) and introduced in one of the Perspectives of this Journal.

This research was collaborated with Doctor Tomohiro NUMATA and Professor Yasuo MORI from Kyoto University and Professor FrankWehner from Max-Planck-Institute of Molecular Physiology and supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science.

add to favorites email to friend print save as pdf

Related Stories

A body temperature sensor, TRPM2, promotes insulin secretion

Jan 04, 2011

The research group led by professor Makoto Tominaga and Dr. Kunitoshi Uchida, National institute for Physiological Sciences (NIPS), Japan, found TRPM2 ion channel in pancreatic beta-cells is important for insulin secretion ...

'Electronic switch' opens doors in rheumatoid joints

Jan 02, 2008

A breakthrough in understanding the way atoms move across cell membranes in the human body could pave the way for the development of new treatments for inflammatory diseases such as rheumatoid arthritis.

Unraveling the mysteries of poison

Apr 13, 2006

Researchers from the Max Planck Institite for Biophysical Chemistry and other German and French colleagues have combined magnetic resonance spectroscopy (solid-state NMR) with special protein synthesis procedures to uncover ...

Recommended for you

Infant cooing, babbling linked to hearing ability

7 hours ago

Infants' vocalizations throughout the first year follow a set of predictable steps from crying and cooing to forming syllables and first words. However, previous research had not addressed how the amount ...

Developing 'tissue chip' to screen neurological toxins

8 hours ago

A multidisciplinary team at the University of Wisconsin-Madison and the Morgridge Institute for Research is creating a faster, more affordable way to screen for neural toxins, helping flag chemicals that ...

Gene mutation discovered in blood disorder

12 hours ago

An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. Studying a family in which ...

Airway muscle-on-a-chip mimics asthma

14 hours ago

The majority of drugs used to treat asthma today are the same ones that were used 50 years ago. New drugs are urgently needed to treat this chronic respiratory disease, which causes nearly 25 million people ...

User comments